BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Seed Health Unveils CODA: Pioneering Computational Biology Platform for Microbiome Research

by BiopharmaTrend   •   April 13, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Seed Health has announced the launch of CODA, a cutting-edge computational biology platform that utilizes the extensive data from the Human Phenotype Project. This project, led by Professor Eran Segal from the Weizmann Institute of Science, boasts the world’s most comprehensive multi-omics data set. CODA is designed to harness this data to forge new paths in the development of precision probiotics and microbiome-directed interventions, with initial focus areas including cardiometabolic health, brain health, menopause, and longevity.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

CODA combines over three million phenotypic data points from more than 13,000 individuals, spanning 40,000 cumulative subject years. This extensive dataset integrates microbiome, genetic, immune, metabolomic, and proteomic analyses, providing a multidimensional view of the factors influencing human health. This integration allows for a deep understanding of the interactions between the microbiome and host health, enabling the development of targeted, outcome-specific interventions.

The CODA Platform

Raja Dhir, co-founder of Seed Health, emphasized the platform's capability to track and analyze health data over extensive periods. This long-term data collection enhances the ability to identify and utilize crucial health connections for the development of precise health interventions. CODA not only advances Seed Health’s microbiome research capabilities but also reinforces the company’s mission to transition scientific discoveries into real-world applications.

The platform also explores the microbiome’s interactions with critical biological systems through its vast dataset, enabling the development of organ-specific biological clocks. These clocks provide insights into the varying aging rates of different organs within the same individual, illustrating the distinction between biological and chronological age. This groundbreaking work underscores the microbiome's potential as a pivotal factor in health interventions.

Further, CODA's research has already led to notable findings, including the influence of microbial genes on body weight and composition, and the interaction between diet and the microbiome in modifying metabolic parameters. These discoveries are set to translate into new consumer health products, enhancing Seed Health’s impact on global health.

With the launch of CODA, Seed Health aims to deepen and expand its understanding of the microbiome’s role in health, driving forward the development of interventions that significantly impact human health. This initiative marks a significant step in realizing the full potential of microbiome science, from infancy to aging, across a broad spectrum of health conditions.

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.